Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~You may be eligible for this study if you:~* Are an HIV-positive woman over 13 years old (need consent if under 18).~* Have lost weight over the past 12 months.~* Are able to eat almost enough to maintain your current weight.~* Agree to practice abstinence or use effective methods of birth control.~* Are on a stable anti-HIV drug regimen or have not been on any anti-HIV drug regimen for the past 30 days.~Exclusion Criteria~You will not be eligible for this study if you:~* Are allergic to nandrolone.~* Have a history of cervical cancer, diabetes, cardiomyopathy or congestive heart failure, or are taking certain medications.~* Have an active opportunistic (HIV-associated) infection or another major illness within 30 days of study entry.~* Have an abnormal PAP smear.~* Have difficulty eating (are on tube-feeding, for example).~* Have severe nausea, vomiting, or diarrhea.~* Have Kaposi's sarcoma (unless stable) or are receiving chemotherapy or radiation for any type of cancer.~* Are pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).